

## **Eleison Announces Issuance of Glufosfamide Patent**

Princeton, NJ, January 8, 2013 -- Eleison Pharmaceuticals LLC, a specialty pharmaceutical company developing life-saving therapeutics for rare cancers, has announced the issuance of United States Patent No. 8,318,683 related to the anti-cancer therapeutic glufosfamide. The newly issued patent describes and claims the use of glufosfamide in monotherapy to treat gemcitabine-refractory pancreatic cancer patients (i.e., 2<sup>nd</sup> line pancreatic cancer), and the use of glufosfamide in combination with gemcitabine for the treatment of pancreatic cancer patients at any stage of disease. A similar patent was issued by the European Patent Office earlier this year, and notices of allowance have been received from Canada, Japan, and South Korea. The issued patents have all been exclusively licensed to Eleison.

## **About Eleison Pharmaceuticals**

Eleison's mission is to acquire, develop, and commercialize clinical stage drug candidates for "orphan" oncology indications, providing new hope for patients with rare life-threatening diseases. The Company has two programs in late-stage development and is in discussions to acquire other promising candidates for rare cancers. Eleison was founded in 2009.

Glufosfamide is a third-generation alkylating agent designed for greater specificity and tumor uptake, with reduced systemic toxicities and side effects. It has been evaluated in more than 450 patients, with promising activity in several cancer types. Eleison plans to begin a pivotal Phase 3 international randomized trial mid-2013, to evaluate the efficacy glufosfamide for the second-line treatment of pancreatic cancer. More than 40,000 Americans die from pancreatic cancer annually, with few therapeutic options to treat the disease and no drugs approved for second-line use.

Eleison has an exclusive worldwide license to ILC, a novel, sustained release formulation of cisplatin in a nanoscale lipid based complex administered via inhalation. ILC was designed to deliver high levels of sustained release cisplatin targeted to the lung, without systemic-related toxicities. Eleison is conducting Phase 2 trial to evaluate the safety and efficacy of ILC for the treatment of pediatric osteosarcoma. Currently, three centers in the U.S. are open for patient enrollment, and additional sites are expected to open in the coming weeks. More information about the study may be found at the <a href="www.clinicaltrials.gov">www.clinicaltrials.gov</a> website. In the U.S., 500 children and young adults are diagnosed with osteosarcoma each year, an often fatal bone cancer.

## **Forward Looking Statements**

Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Eleison's product candidates, their uses and potential benefits and clinical trial results and plans. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, capital sufficiency, Eleison's ability to enroll and complete its current and anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, the possibility that results from these trials will not be confirmed, potential adverse side effects, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Eleison does not intend to update any forward-looking statement made in this news release.

SOURCE/CONTACT: Eleison Pharmaceuticals LLC

Corporate Communications 103 Carnegie Center, Suite 300

Princeton, NJ 08540 tel : 215-554-3530

email: info@eleison-pharma.com